Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jänne, Pasi A., Baik, Christina, Su, Wu-Chou, Johnson, Melissa L., Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A., Steuer, Conor E., Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, Yu, Helena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401524/
https://www.ncbi.nlm.nih.gov/pubmed/34548309
http://dx.doi.org/10.1158/2159-8290.CD-21-0715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401524/
https://www.ncbi.nlm.nih.gov/pubmed/34548309
http://dx.doi.org/10.1158/2159-8290.CD-21-0715

Ejemplares similares